Clinicopathologic spectrum of drug nephrotoxicity.
D000617:Aminoglycosides / Q000009:adverse effects; D000700:Analgesics / Q000009:adverse effects; D000900:Anti-Bacterial Agents / Q000009:adverse effects; D000893:Anti-Inflammatory Agents / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000009:adverse effects; D002216:Captopril / Q000009:adverse effects; D002927:Cimetidine / Q000009:adverse effects; D003287:Contrast Media / Q000009:adverse effects; D003524:Cyclosporins / Q000009:adverse effects; D064420:Drug-Related Side Effects and Adverse Reactions; D005921:Glomerulonephritis / Q000139:chemically induced; D006046:Gold / Q000009:adverse effects; D006801:Humans; D007511:Ischemia; D007668:Kidney / Q000098:blood supply; D007674:Kidney Diseases / Q000139:chemically induced*; D052177:Kidney Diseases, Cystic / Q000139:chemically induced; D007681:Kidney Papillary Necrosis / Q000139:chemically induced; D007683:Kidney Tubular Necrosis, Acute / Q000139:chemically induced; D008094:Lithium / Q000009:adverse effects; D009404:Nephrotic Syndrome / Q000139:chemically induced; D014118:Toxins, Biological / Q000009:adverse effects
D000617:Aminoglycosides; D000700:Analgesics; D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; D000970:Antineoplastic Agents; D003287:Contrast Media; D003524:Cyclosporins; D014118:Toxins, Biological; D006046:Gold; D002927:Cimetidine; D008094:Lithium; D002216:Captopril